Proactive Investors - Run By Investors For Investors

Hemispherx Biopharma extends $8M rights offering to March 5

The offering will fund the biopharmaceutical company’s trials for its anti-cancer agent Ampligen
traders
All members of the Ocala, Florida-based company’s senior management are participating in the offering

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) said Thursday it has extended the subscription period for its $8 million rights offering until 5 pm ET on March 5, 2019.

Proceeds from the offering will be used to fund the biopharmaceutical company’s trials for its anti-cancer agent Ampligen.

According to the terms of the deal, the pricing remains $1,000 per unit, consisting of one share of Series B convertible preferred stock with a stated value of $1,000 (and immediately convertible into Hemispherx’s common stock) and warrants to purchase Hemispherx’s common stock.

READ: Hemispherx Biopharma's cancer drug Ampligen to be used in new oncology study

The Series B convertible preferred stock conversion price will now be $0.20 and each unit will now consist of 5,000 warrants to purchase Hemispherx’s common stock at an adjusted exercise price of $0.20. The warrants will be exercisable for five years after the date of issuance.

Holders of stock or related options and warrants who wish to participate in the rights offering must deliver a signed subscription rights statement, along with payment, to the subscription agent via mail, hand or overnight courier, before 5 pm ET on March 5.

The subscription agent is American Stock Transfer & Trust Company LLC.

READ: Hemispherx Biopharma started with a Buy rating at Ascendiant Capital Markets

All of the members of the Ocala, Florida-based company’s senior management and board of directors are planning to participate in the rights offering, the company said.

Hemispherx’s flagship products include the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancer, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.

Hemispherx shares added 6.26% to finish at US$0.18 on Wednesday.

View full HEB profile View Profile

Hemispherx Biopharma Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use